The Case for Immunotherapy Trials That Reflect the Real World of Metastatic Melanoma
The problem of low representation of racial minorities is especially urgent during the era of immunotherapy trials.
Bone Cancer
BONE CANCER ADVISOR
FEATURED CONTENT
-
-
Ribociclib Shown to Penetrate the Blood-Brain Barrier in Glioblastoma
A phase 0 study of ribociclib in patients with recurrent glioblastoma seeks to inform the feasibility of the use of CDK 4/6 inhibitors for deadly brain tumors. -
Treatment Delays With CAR-T Therapy: A High Price to Pay
A treatment delay of 6 months was found to result in up to a 67.3% loss in social value for patients receiving chimeric antigen receptor T-cell therapy. -
Phase 3 Trial for Oncolytic Viral Therapy Pexa-Vec in Advanced Liver Cancer Terminated Early
Pexa-Vec, in combination with sorafenib, has failed an interim futility analysis, leading to the early termination of the trial. -
Microbiome Analysis May Be a Feasible Diagnostic Test for Prostate Cancer
The microbiome could have a role in the diagnosis of PrCa.
BONE CANCER NEWS
FDA Grants Orphan Drug Designation to BN-Brachyury for Chordoma
CTA Treatment Regimen Chart for Bone Cancer Updated
Baseline EFS Outcomes Identified for Recurrent/Refractory Pediatric Osteosarcoma
In Giant Cell Tumor of Bone, Denosumab Shows Robust Clinical Efficacy
Pacritinib Reduces Spleen Volume in Patients with Myelofibrosis
Want to read more?
Please login or register first to view this content.
Next post in General Oncology
